Saturday, August 31, 2024 5:49:54 AM
Interesting .. also from Google...
A response to this query...
Response...
A response to this query...
what is unique about atossa therapeutics inc
Response...
Is Atossa Therapeutics a good buy?
Why is Atossa stock dropping?
Who owns Atossa Therapeutics?
What is the target price for Atossa Genetics?
Stock Price Target ATOS
High $6.25
Median $6.00
Low $4.00
Average $5.42
Current Price $1.39
ATOS | Atossa Therapeutics Inc. Analyst Estimates & Rating - WSJ
WSJ
https://www.wsj.com › quotes › ATOS › research-ratings
Search for: What is the target price for Atossa Genetics?
What is the stock price forecast for Atossa Therapeutics in 2025?
What does Atossa Therapeutics do?
Recent ATOS News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:27:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:25:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:25:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:24:42 PM
- Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer • PR Newswire (US) • 05/14/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 12:45:18 PM
- Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update • PR Newswire (US) • 05/08/2026 12:45:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 12:30:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 12:00:17 PM
- Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women • PR Newswire (US) • 05/06/2026 12:30:00 PM
- Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome • PR Newswire (US) • 05/04/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2026 12:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/30/2026 11:22:50 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/30/2026 09:33:51 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/30/2026 09:30:46 PM
- Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update • PR Newswire (US) • 03/25/2026 09:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/25/2026 09:21:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 09:20:21 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/20/2026 08:52:24 PM
- The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology • GlobeNewswire Inc. • 03/19/2026 03:00:00 PM
- Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives • PR Newswire (US) • 03/19/2026 12:00:00 PM
- Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference • PR Newswire (US) • 03/12/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2026 09:22:08 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/20/2026 09:16:05 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/20/2026 09:07:14 PM

